Lentiviral Vector Contract Development And Manufacturing Organizations Market Size (2024 - 2029)

Lentiviral Vector Contract Development And Manufacturing Organizations Market Analysis

The Lentiviral Vector Contract Development And Manufacturing Organizations Market size is estimated at USD 161.64 million in 2024, and is expected to reach USD 231.89 million by 2029, growing at a CAGR of 6.20% during the forecast period (2024-2029).

Cell and gene therapy's growing emphasis and development are expected to contribute to the lentiviral vector CDMO market growth. Cell and gene therapies have demonstrated remarkable success in treating previously untreatable or difficult-to-treat diseases, including certain types of cancer, genetic disorders, and autoimmune conditions. For instance, in September 2023, BioViros, a full-service CDMO specializing in lentiviral vectors for cell and gene therapy, announced the opening of its state-of-the-art laboratory for lentiviral vectors in New Zealand. Additionally, in January 2023, Vector BioMed has innovated a technological platform for designing and producing lentiviruses utilized in cell and gene therapy delivery.

Moreover, increasing fundraising activities by the market players to expand the CDMO services is likely to contribute to the market growth. For instance, in January 2023, iVexSol Inc., a CDMO, announced USD 23.8 million in Series A-3 funding. The new funding will be used to invest in iVexSol’s Intelligent Vector Solutions by advancing process and analytical technologies, expanding technical teams in Quality, Regulatory, and cGMP operations, and augmenting existing infrastructure to support the production of stable lentiviral vector (LVV) producer cell lines.

Similarly, in January 2023, Vector BioMed commenced operations as a CDMO, receiving financial backing from Viking Global Investors and Casdin Capital's seed round. These funds will facilitate the scaling of commercial operations, enabling prompt delivery of premium lentiviral vectors for preclinical research, clinical trials, and commercial use. Vector BioMed specializes in providing solutions that empower partners to advance their lentiviral vector-based treatments into clinical trials, thereby expediting their journey to commercialization.

The heightened focus on cell and gene therapy and the surge in investment in lentiviral vector-based therapeutics, coupled with market players' strategic initiatives, are projected to propel market growth.Nevertheless, the limitations in scalability and the challenges with downstream purification are anticipated to limit market expansion during the forecast period.

Lentiviral Vector Contract Development And Manufacturing Organizations Industry Segmentation

As per the scope of the report, the lentiviral vector CDMO market refers to the industry segment that specializes in providing services related to the development and manufacturing of lentiviral vectors for various applications, particularly in the field of gene therapy. Lentiviral vector contract development and manufacturing organizations market is segmented by component, disease indication, end user, and geography. By component, the market is segmented as lentiviral promoter, lentiviral fusion tags, lentivirus packaging systems, and other components. By disease indication, the market is segmented as cancer, genetic disorders, infectious diseases, veterinary diseases, and other disease indications. By end user, the market is segmented as pharmaceutical and biotech, academic research, and other end users. By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.